Healthcare Industry News: Magnetic Resonance Imaging
News Release - November 30, 2009
Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy
CHICAGO, Nov. 30 -- (Healthcare Sales & Marketing Network) -- Dr. Jocelyn Rapelyea, Associate Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., demonstrated how occult lesions identified with Breast-Specific Gamma Imaging (BSGI) can be localized utilizing multi-modality imaging for needle biopsy as well, as for pre-operative localization today at the annual meeting of the Radiological Society of North America (RSNA).The exhibit demonstrated how to use minimally invasive approaches to biopsy BSGI detected occult lesions using correlative imaging with mammography, ultrasound, Magnetic Resonance Imaging (MRI) and BSGI. In addition, it describes a technique for preoperative bracketing to guide lumpectomy procedures. The lesions biopsied in this study included invasive cancer, Ductal carcinoma in situ (DCIS), ADH, lobular neoplasia as well as benign lesions including fibroadenomas, fat necrosis and FDC.
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.
Source: Dilon Diagnostics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
